Table 2.
Clinical data of the subgroups classified by the methylation level of the intragenic CpG island of PDX1, EN2, and MSX1; this data includes several patients, age, sex, cancer stage, invasion to adjacent tissues, cancer differentiation levels, microsatellite stability, and the origin of the tumor site.
| Parameter | Subgroup 1 | Subgroup 2 | P |
|---|---|---|---|
| N | 25 | 61 | |
| Age, mean (range), year | 58.2 (40–74) | 63.2 (36–83) | 0.0343* |
| Sex (male:female) | 13:12 | 39:22 | 0.304, ns |
| Stage | n = 25 | n = 61 | |
| I | 0% (0) | 1.64% (1) | 2.113E-06*** |
| II | 8% (2) | 0% (0) | |
| III | 20% (5) | 78.7% (48) | |
| IV | 72% (18) | 26.2% (12) | |
| Invasion | n = 25 | n = 61 | |
| Lymphatic | 56% (14) | 45.9% (19) | 0.0314* |
| Vascular | 44% (11) | 19.6% (8) | 0.00172** |
| Perineural | 80% (20) | 50.8% (31) | 0.0124* |
| Differentiation | n = 24 | n = 58 | |
| Well | 0% (0) | 1.7% (1) | 0.706, ns |
| Moderate | 91.7% (22) | 93.1% (54) | |
| Poor | 8.3% (2) | 5.2% (3) | |
| Microsatellite | n = 23 | n = 58 | |
| Stable | 91.3% (21) | 93.1% (54) | 0.969, ns |
| Instable - Low | 4.3% (1) | 5.2% (3) | |
| Instable - High | 4.3% (1) | 5.2% (3) | |
| Site of Tumor | n = 25 | n = 58 | |
| Ascending | 20% (5) | 25.9% (15) | 0.667, ns |
| Descending | 4% (1) | 0% (0) | |
| Transverse | 4% (1) | 1.7% (1) | |
| Sigmoid | 40% (10) | 36.2% (21) | |
| Rectal | 16% (4) | 20.7% (12) | |
| Rectosigmoid Junction | 16% (4) | 15.5% (9) |
The age of the two subgroups was compared via a two-tailed t test, and the chi-square test was used to analyze the other parameters. Significance levels are presented as ns: nonsignificant, *p < 0.05, **p < 0.01, ***p < 0.001.